MirimGENE Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

MirimGENE General Information

Description

Developer of immunity drugs intended to offer personalized precision medicine to treat infectious diseases. The company targets a new endogenous immune activation factor network to develop innovative new drugs that can treat infectious diseases with no treatment and high mortality and intractable immune diseases that are resistant to existing drugs, enabling medical practitioners to treat patients who cannot be treated with existing treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 155 Gaetbeol-ro
  • Room S215, Yeonsu-gu
  • Incheon
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 155 Gaetbeol-ro
  • Room S215, Yeonsu-gu
  • Incheon
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MirimGENE Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 01-Aug-2021 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Oct-2020 $170K $170K Completed Startup
1. Seed Round 31-Aug-2020 Completed Startup
To view MirimGENE’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

MirimGENE Patents

MirimGENE Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4835063-A1 Novel anti-tuberculosis engineered protein, and use thereof Pending 26-Dec-2023
WO-2025143797-A1 Novel anti-tuberculosis engineered protein, and use thereof Inactive 26-Dec-2023
EP-4516812-A1 Anti-wars1 antibody and use thereof Pending 27-Apr-2022
EP-4516812-A4 Anti-wars1 antibody and use thereof Pending 27-Apr-2022
US-20250289905-A1 Anti-wars1 antibody and use thereof Pending 27-Apr-2022 C07K16/40
To view MirimGENE’s complete patent history, request access »

MirimGENE Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MirimGENE Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Honest Ventures Venture Capital Minority
KDB Capital PE/Buyout Minority
L&S Venture Capital Venture Capital Minority
Magna Investment (Seoul) Venture Capital Minority
Samho Green Investment Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

MirimGENE FAQs

  • When was MirimGENE founded?

    MirimGENE was founded in 2019.

  • Where is MirimGENE headquartered?

    MirimGENE is headquartered in Incheon, South Korea.

  • What is the size of MirimGENE?

    MirimGENE has 3 total employees.

  • What industry is MirimGENE in?

    MirimGENE’s primary industry is Drug Discovery.

  • Is MirimGENE a private or public company?

    MirimGENE is a Private company.

  • What is MirimGENE’s current revenue?

    The current revenue for MirimGENE is .

  • How much funding has MirimGENE raised over time?

    MirimGENE has raised $7.56M.

  • Who are MirimGENE’s investors?

    Honest Ventures, KDB Capital, L&S Venture Capital, Magna Investment (Seoul), and Samho Green Investment are 5 of 7 investors who have invested in MirimGENE.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process